15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8192746B2 · kind B2 · utility
33Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2011 |
| Grant date | Jun 5, 2012 |
| Priority date | — |
| Expiry date | Feb 3, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6037
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197. The immunogenic composition, preferably formulated as a vaccine on an aluminum -based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.